Autoimmune polyendocrine syndrome overview: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Historical Perspective== | ==Historical Perspective== | ||
In 19th century [[physicians]] first focussed their attention on constellation of [[symptoms]] associated with autoimmune polyendocrine syndrome. In 1855, [[Thomas Addison]] identified patients with [[Addison's disease]] who also appeared to have coexisting [[pernicious anemia]]. In 1956, Roitt and Doniach found that patients with [[Hashimoto's thyroiditis]] had circulating [[autoantibodies]] reacting with [[thyroid gland]]. In 1980, Neufeld and Blizzard first developed the classification for [[polyglandular]] [[failure]] and in 1982 categorised autoimmune polyendocrine syndrome into type 1 and type 2. | |||
==Classification== | ==Classification== | ||
Revision as of 18:14, 5 October 2017
|
Autoimmune polyendocrine syndrome Microchapters |
|
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune polyendocrine syndrome overview On the Web |
|
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome overview |
|
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
|
Risk calculators and risk factors for Autoimmune polyendocrine syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
In 19th century physicians first focussed their attention on constellation of symptoms associated with autoimmune polyendocrine syndrome. In 1855, Thomas Addison identified patients with Addison's disease who also appeared to have coexisting pernicious anemia. In 1956, Roitt and Doniach found that patients with Hashimoto's thyroiditis had circulating autoantibodies reacting with thyroid gland. In 1980, Neufeld and Blizzard first developed the classification for polyglandular failure and in 1982 categorised autoimmune polyendocrine syndrome into type 1 and type 2.